Showing results (1-10 of 636) with videos related to
Sort By:
Pageof 64
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on PracticeAmy E DeZern, Luca Malcovati, Benjamin L EbertHematology. American Society of Hematology. Education Program|December 6, 2015
Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?Amy E DeZernHematology. American Society of Hematology. Education Program|December 10, 2021
Lower risk but high riskAmy E DeZernHematology. American Society of Hematology. Education Program|December 4, 2018
Treatments targeting MDS genetics: a fool's errand?Amy E DeZernClinical Lymphoma & Myeloma|September 26, 2009
Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromesLuca MalcovatiLeukemia Research|December 6, 2007
Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromesLuca MalcovatiClinical Lymphoma, Myeloma & Leukemia|July 11, 2026
SOHO State of the Art Updates and Next Questions | Progress in Higher-Risk Myelodysplastic SyndromesCarlotta Pazzi, Amy E DeZernBlood|November 14, 2024
Imetelstat: a new addition to the therapeutic landscape of lower-risk MDSYasmin Abaza, Amy E DeZernBest Practice & Research. Clinical Haematology|August 18, 2021
Biology and clinical management of hypoplastic MDS: MDS as a bone marrow failure syndromeTheodoros Karantanos, Amy E DeZernNEJM Evidence|February 6, 2024
How Great Is the Threat of Clonal Hematopoiesis? Let This New Risk Score Be Your GuideZhuoer Xie, Amy E DeZernPageof 64